| Literature DB >> 34661369 |
Christine Helsen1, Frank Claessens1, Sarah El Kharraz1, Vanessa Dubois2, Martin E van Royen3, Adriaan B Houtsmuller3, Ekatarina Pavlova4, Nina Atanassova4, Tien Nguyen5, Arnout Voet5, Roy Eerlings1, Florian Handle1, Stefan Prekovic1,6, Elien Smeets1, Lisa Moris1, Wout Devlies1, Claes Ohlsson7, Matti Poutanen7,8, Kevin J Verstrepen9, Geert Carmeliet2, Kaisa-Mari Launonen10, Laura Helminen10, Jorma J Palvimo10, Claude Libert11,12, Dirk Vanderschueren2.
Abstract
Whereas dimerization of the DNA-binding domain of the androgen receptor (AR) plays an evident role in recognizing bipartite response elements, the contribution of the dimerization of the ligand-binding domain (LBD) to the correct functioning of the AR remains unclear. Here, we describe a mouse model with disrupted dimerization of the AR LBD (ARLmon/Y ). The disruptive effect of the mutation is demonstrated by the feminized phenotype, absence of male accessory sex glands, and strongly affected spermatogenesis, despite high circulating levels of testosterone. Testosterone replacement studies in orchidectomized mice demonstrate that androgen-regulated transcriptomes in ARLmon/Y mice are completely lost. The mutated AR still translocates to the nucleus and binds chromatin, but does not bind to specific AR binding sites. In vitro studies reveal that the mutation in the LBD dimer interface also affects other AR functions such as DNA binding, ligand binding, and co-regulator binding. In conclusion, LBD dimerization is crucial for the development of AR-dependent tissues through its role in transcriptional regulation in vivo. Our findings identify AR LBD dimerization as a possible target for AR inhibition.Entities:
Keywords: androgen receptor; chromatin binding; dimerization; ligand-binding domain; transcriptional activation
Mesh:
Substances:
Year: 2021 PMID: 34661369 PMCID: PMC8647150 DOI: 10.15252/embr.202152764
Source DB: PubMed Journal: EMBO Rep ISSN: 1469-221X Impact factor: 8.807